Compare BBAI & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBAI | WGS |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | EDP Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | BBAI | WGS |
|---|---|---|
| Price | $3.35 | $60.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $130.71 |
| AVG Volume (30 Days) | ★ 24.3M | 659.3K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.89 | $29.98 |
| Revenue Next Year | $11.71 | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.36 | $55.17 |
| 52 Week High | $9.39 | $170.87 |
| Indicator | BBAI | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 36.12 |
| Support Level | $3.01 | $55.18 |
| Resistance Level | $4.42 | $95.75 |
| Average True Range (ATR) | 0.23 | 4.22 |
| MACD | 0.03 | 0.34 |
| Stochastic Oscillator | 44.23 | 32.57 |
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.